Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells

Yang Gao, Melissa J. Romero-Aleshire, Qi Cai, Theodore J. Price, Heddwen L Brooks

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Nephrogenic diabetes insipidus (NDI) is the most common renal side effect in patients undergoing lithium therapy for bipolar affective disorders. Approximately 2 million US patients take lithium of whom ~50% will have altered renal function and develop NDI (2, 37). Lithium-induced NDI is a defect in the urinary concentrating mechanism. Lithium therapy also leads to proliferation and abundant renal cysts (microcysts), commonly in the collecting ducts of the cortico-medullary region. The mTOR pathway integrates nutrient and mitogen signals to control cell proliferation and cell growth (size) via the mTOR Complex 1 (mTORC1). To address our hypothesis that mTOR activation may be responsible for lithium-induced proliferation of collecting ducts, we fed mice lithium chronically and assessed mTORC1 signaling in the renal medulla. We demonstrate that mTOR signaling is activated in the renal collecting ducts of lithium-treated mice; lithium increased the phosphorylation of rS6 (Ser240/Ser244), p-TSC2 (Thr1462), and p-mTOR (Ser2448). Consistent with our hypothesis, treatment with rapamycin, an allosteric inhibitor of mTOR, reversed lithium-induced proliferation of medullary collecting duct cells and reduced levels of p-rS6 and p-mTOR. Medullary levels of p-GSK3β were increased in the renal medullas of lithium-treated mice and remained elevated following rapamycin treatment. However, mTOR inhibition did not improve lithium-induced NDI and did not restore the expression of collecting duct proteins aquaporin-2 or UT-A1.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Renal Physiology
Volume305
Issue number8
DOIs
StatePublished - Oct 15 2013

Fingerprint

Sirolimus
Lithium
Kidney
Nephrogenic Diabetes Insipidus
Inhibition (Psychology)
Aquaporin 2
Cell Enlargement
Therapeutics
Mood Disorders
Bipolar Disorder
Mitogens
Cysts
Phosphorylation
Cell Proliferation
Food

Keywords

  • Aquaporin-2
  • Collecting ducts
  • GSK3ß
  • Urea transporter

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells. / Gao, Yang; Romero-Aleshire, Melissa J.; Cai, Qi; Price, Theodore J.; Brooks, Heddwen L.

In: American Journal of Physiology - Renal Physiology, Vol. 305, No. 8, 15.10.2013.

Research output: Contribution to journalArticle

@article{a7660404e6a24c87b69fb9808166feff,
title = "Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells",
abstract = "Nephrogenic diabetes insipidus (NDI) is the most common renal side effect in patients undergoing lithium therapy for bipolar affective disorders. Approximately 2 million US patients take lithium of whom ~50{\%} will have altered renal function and develop NDI (2, 37). Lithium-induced NDI is a defect in the urinary concentrating mechanism. Lithium therapy also leads to proliferation and abundant renal cysts (microcysts), commonly in the collecting ducts of the cortico-medullary region. The mTOR pathway integrates nutrient and mitogen signals to control cell proliferation and cell growth (size) via the mTOR Complex 1 (mTORC1). To address our hypothesis that mTOR activation may be responsible for lithium-induced proliferation of collecting ducts, we fed mice lithium chronically and assessed mTORC1 signaling in the renal medulla. We demonstrate that mTOR signaling is activated in the renal collecting ducts of lithium-treated mice; lithium increased the phosphorylation of rS6 (Ser240/Ser244), p-TSC2 (Thr1462), and p-mTOR (Ser2448). Consistent with our hypothesis, treatment with rapamycin, an allosteric inhibitor of mTOR, reversed lithium-induced proliferation of medullary collecting duct cells and reduced levels of p-rS6 and p-mTOR. Medullary levels of p-GSK3β were increased in the renal medullas of lithium-treated mice and remained elevated following rapamycin treatment. However, mTOR inhibition did not improve lithium-induced NDI and did not restore the expression of collecting duct proteins aquaporin-2 or UT-A1.",
keywords = "Aquaporin-2, Collecting ducts, GSK3{\ss}, Urea transporter",
author = "Yang Gao and Romero-Aleshire, {Melissa J.} and Qi Cai and Price, {Theodore J.} and Brooks, {Heddwen L}",
year = "2013",
month = "10",
day = "15",
doi = "10.1152/ajprenal.00153.2013",
language = "English (US)",
volume = "305",
journal = "American Journal of Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "8",

}

TY - JOUR

T1 - Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells

AU - Gao, Yang

AU - Romero-Aleshire, Melissa J.

AU - Cai, Qi

AU - Price, Theodore J.

AU - Brooks, Heddwen L

PY - 2013/10/15

Y1 - 2013/10/15

N2 - Nephrogenic diabetes insipidus (NDI) is the most common renal side effect in patients undergoing lithium therapy for bipolar affective disorders. Approximately 2 million US patients take lithium of whom ~50% will have altered renal function and develop NDI (2, 37). Lithium-induced NDI is a defect in the urinary concentrating mechanism. Lithium therapy also leads to proliferation and abundant renal cysts (microcysts), commonly in the collecting ducts of the cortico-medullary region. The mTOR pathway integrates nutrient and mitogen signals to control cell proliferation and cell growth (size) via the mTOR Complex 1 (mTORC1). To address our hypothesis that mTOR activation may be responsible for lithium-induced proliferation of collecting ducts, we fed mice lithium chronically and assessed mTORC1 signaling in the renal medulla. We demonstrate that mTOR signaling is activated in the renal collecting ducts of lithium-treated mice; lithium increased the phosphorylation of rS6 (Ser240/Ser244), p-TSC2 (Thr1462), and p-mTOR (Ser2448). Consistent with our hypothesis, treatment with rapamycin, an allosteric inhibitor of mTOR, reversed lithium-induced proliferation of medullary collecting duct cells and reduced levels of p-rS6 and p-mTOR. Medullary levels of p-GSK3β were increased in the renal medullas of lithium-treated mice and remained elevated following rapamycin treatment. However, mTOR inhibition did not improve lithium-induced NDI and did not restore the expression of collecting duct proteins aquaporin-2 or UT-A1.

AB - Nephrogenic diabetes insipidus (NDI) is the most common renal side effect in patients undergoing lithium therapy for bipolar affective disorders. Approximately 2 million US patients take lithium of whom ~50% will have altered renal function and develop NDI (2, 37). Lithium-induced NDI is a defect in the urinary concentrating mechanism. Lithium therapy also leads to proliferation and abundant renal cysts (microcysts), commonly in the collecting ducts of the cortico-medullary region. The mTOR pathway integrates nutrient and mitogen signals to control cell proliferation and cell growth (size) via the mTOR Complex 1 (mTORC1). To address our hypothesis that mTOR activation may be responsible for lithium-induced proliferation of collecting ducts, we fed mice lithium chronically and assessed mTORC1 signaling in the renal medulla. We demonstrate that mTOR signaling is activated in the renal collecting ducts of lithium-treated mice; lithium increased the phosphorylation of rS6 (Ser240/Ser244), p-TSC2 (Thr1462), and p-mTOR (Ser2448). Consistent with our hypothesis, treatment with rapamycin, an allosteric inhibitor of mTOR, reversed lithium-induced proliferation of medullary collecting duct cells and reduced levels of p-rS6 and p-mTOR. Medullary levels of p-GSK3β were increased in the renal medullas of lithium-treated mice and remained elevated following rapamycin treatment. However, mTOR inhibition did not improve lithium-induced NDI and did not restore the expression of collecting duct proteins aquaporin-2 or UT-A1.

KW - Aquaporin-2

KW - Collecting ducts

KW - GSK3ß

KW - Urea transporter

UR - http://www.scopus.com/inward/record.url?scp=84885604333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885604333&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00153.2013

DO - 10.1152/ajprenal.00153.2013

M3 - Article

C2 - 23884148

AN - SCOPUS:84885604333

VL - 305

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6143

IS - 8

ER -